IMRX · Immuneering Corporation

Immuneering Corporation announced its first quarter 2026 financial results alongside significant clinical progress for its lead candidate atebimetinib. The company reported a GAAP net loss of $13.5 million, or $0.21 per share, an improvement from $15.0 million, or $0.42 per share, in the prior year period, driven by lower R&D expenses of $10.6 million versus $11.5 million, primarily from reduced spend on the envometinib program, offset by increased costs for atebimetinib and preclinical efforts. G&A expenses rose to $4.7 million from $4.0 million due to higher employee and professional fees. Cash position stood at $198.6 million as of March 31, 2026, down from $217.0 million at year-end 2025, supporting operations into 2029 without needing near-term financing. CEO Ben Zeskind highlighted upcoming ASCO oral presentation on June 1, 2026, of survival data from 55 first-line metastatic pancreatic cancer patients treated with atebimetinib plus mGnP, building momentum toward the pivotal Phase 3 MAPKeeper 301 trial, now recruiting with first dosing targeted mid-2026. Additional updates include genetic data from AACR showing rare MAPK alterations in 123 patients, suggesting sustained benefits, and a remarkable 27-month progression-free survival in a third-line patient with 85% tumor reduction and improved quality of life. A Phase 2 lung cancer trial with Libtayo is set to dose first patient in 2H 2026. These developments underscore atebimetinib's potential as a Deep Cyclic Inhibitor to enhance survival and tolerability in MAPK-driven cancers.